DiaSorin SpA
Fernando Davico has over 20 years of experience in various managerial roles in the healthcare industry. Fernando most recently served as the Corporate Vice President of Sales for EMEA, APAC, and LATAM at DiaSorin since April 2018. Prior to that, they were the Vice President and General Manager for Latin America at Hologic, Inc. from May 2016 to April 2018. Before that, they held multiple positions at Johnson & Johnson - Ortho Clinical Diagnostics, including Regional Business Director for Latin America and Business Director for Brazil. Fernando also served as the Chief Financial Officer at Villalonga Furlong and the Chief Operating Officer of the Healthcare Business Unit at The Exxel Group. Overall, Fernando Davico has demonstrated expertise in sales, business management, and financial planning.
Fernando Davico attended Instituto Balseiro at Universidad Nacional de Cuyo from 1989 to 1992 where they pursued a degree in Nuclear Engineering. Fernando then continued their education at IDEA in 1992 to 1993, obtaining an MBA.
This person is not in any offices
DiaSorin SpA
4 followers
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company's business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.